Bemarituzumab (FUT8-KO)

Cat. No.: HY-P99010A Purity: 99.00%: Data Sheet
COA

SDS

FAQs
Technical Support

Bemarituzumab (FUT8-KO) is an anti-FGFR2b monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa.

For research use only. We do not sell to patients.

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Interleukin Related Isoform Specific Products:

View All Isoforms

IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

Biological Activity
Purity & Documentation
References
Customer Review

Description	Bemarituzumab (FUT8-KO) is an anti-FGFR2b monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa^[1].
Isotype	Human IgG1 kappa
Recommend Isotype Controls	Human IgG1 kappa, Isotype Control
In Vitro	The most extensively characterized aberration in fucosyltransferase (FUT) function in cancer is FUT8-mediated core fucosylation. FUT8 is frequently upregulated in human tumors. Depletion of FUT8 effectively blocks tumor growth and metastasis. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Bemarituzumab (FUT8-KO) Related Antibodies
Application	ELISA, FACS, Functional assay
Conjugated	Unconjugated
Reconsititution	The product can be reconstituted/diluted with sterile PBS or saline.
Molecular Weight	143.86 kDa
Appearance	Liquid
Color	Colorless to light yellow
SMILES	[Bemarituzumab (FUT8-KO)]
Shipping	Shipping with dry ice.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity	Immobilized hu-FGFR2-β-IIIb-ECD-His can bind Bemarituzumab (FUT8-KO). The EC₅₀ for this effect is 19.97 ng/mL. Loaded Bemarituzumab (FUT8-KO) on AHC2 biosensor, can bind FGFR-2 beta (IIIb) Protein, Human (HEK293, His, HY-P72646) with an affinity constant of 2.530E-09 M as determined in BLI assay.
Purity & Documentation	Purity: 99.74% Select Batch: Data Sheet (256 KB) SDS (251 KB) COA (232 KB) SDS-PAGE (86 KB) SEC-HPLC (214 KB) Inhibitory Antibodies User Guide (602 KB)
References	[1]. Xiang H, et al., Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer. MAbs. 2021 Jan-Dec;13(1):1981202. [Content Brief]